Acute Pain News and Research

RSS

FDA approves Iroko Pharmaceuticals’ ZORVOLEX capsules

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved ZORVOLEX™ (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the treatment of mild to moderate acute pain in adults. ZORVOLEX was approved at dosage strengths that are 20 percent lower than currently available diclofenac products.

19 Oct 2013

$Vertebral augmentation for spinal fractures improves patient survival, reduces overall costs$

Vertebral augmentation for spinal fractures improves patient survival, reduces overall costs

A study of 69,000 Medicare patient records led by Johns Hopkins researchers shows that people with spine compression fractures who undergo operations to strengthen back bones with cement survive longer and have shorter overall hospital stays than those who stick with bed rest, pain control and physical therapy.

18 Oct 2013

ESTEVE reports positive top line results from E-58425 phase II trial for acute pain

ESTEVE, a pharmaceutical company focused on developing novel therapeutics for pain today announces positive top line results from its recently completed phase II trial, which was designed to evaluate the efficacy and safety of E-58425 in acute pain.

16 Oct 2013

Polyamine-deficient diets effective as pain relief treatment for chronic and acute pain

Before and after spinal surgery, patients on a polyamine-deficient diets experienced significant relief of both chronic and acute pain, according to a study presented at the ANESTHESIOLOGY 2013 annual meeting.

14 Oct 2013

Team Ritter to raise funds for John Ritter Foundation for Aortic Health at ING NYC Marathon

Friends and family members of people with thoracic aortic disease and fans of the late legendary comedic actor John Ritter will come together as Team Ritter to raise funds for the John Ritter Foundation for Aortic Health at the ING New York City Marathon on Nov. 3, 2013.

10 Oct 2013

MNK-795 for acute pain management: an interview with Dr Lynn Webster

MNK-795 is a product in development that is intended to be used for acute pain. It has some unique properties. First, it is an extended release formulation, meaning that it’s going to last more than three to four hours. It was studied to be dosed once every 12 hours, and that is unique for an acute pain formulation.

8 Oct 2013

AcelRx Pharmaceuticals submits Zalviso NDA to FDA

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it submitted a New Drug Application to the U.S. Food and Drug Administration for Zalviso (sufentanil sublingual microtablet system).

30 Sep 2013

Arginine therapy may be safe treatment for patients with sickle cell disease

Arginine therapy may be a safe and inexpensive treatment for acute pain episodes in patients with sickle cell disease, according to results of a recent clinical study. The study was the first randomized placebo-controlled study to demonstrate benefits of arginine therapy in children with sickle cell disease hospitalized for severe pain.

17 Sep 2013

NIH budget slashing may stall future pain research funding

Multi-faceted pain research discoveries within the last decade are bringing new hope for the estimated 100 million Americans with chronic pain. Unfortunately, translation of these scientific advances into clinical practice could be stalled without sufficient funding for both basic science and clinical pain research, according to the American Pain Society.

12 Sep 2013

FDA schedules meeting on 3 October to discuss QRxPharma's MOXDUO NDA for acute pain

QRxPharma Limited announced today the United States Food and Drug Administration has scheduled a meeting on 3 October to discuss the Company's MOXDUO New Drug Application for the treatment of moderate to severe acute pain.

6 Sep 2013

Drug for children with sickle cell anemia reduces hospitalizations and treatment costs

A drug proven effective for treatment of adults and children with sickle cell anemia reduced hospitalizations and cut annual estimated medical costs by 21 percent for affected infants and toddlers, according to an analysis led by St. Jude Children's Research Hospital. The report appears today in the advance online edition of the journal Pediatrics.

2 Sep 2013

Mallinckrodt to present MNK-795 clinical data at PAINWeek 2013

Mallinckrodt announced today that the first clinical data on MNK-795 will be presented at PAINWeek 2013, to be held September 4-7 in Las Vegas. MNK-795 is an extended-release oral formulation of oxycodone and acetaminophen that has been studied in clinical trials for the management of moderate to severe acute pain where the use of an opioid analgesic is appropriate.

29 Aug 2013

Reformulated OxyContin®: an interview with Dr. Paul Coplan, Executive Director, Risk Management and Epidemiology, Purdue Pharma

OxyContin contains oxycodone, which is an opioid agonist. It is used for the management of moderate to severe pain when a constant opioid analgesic is needed for a prolonged period of time.

29 Aug 2013

Few physicians receive adequate training to help patients with chronic pain

Pain is the most common reason a patient sees a physician but few physicians have received adequate training to help their patients, according to a Henry Ford Hospital article published in the Journal of American Osteopathic Association.

13 Aug 2013

MEDNAX acquires Holston Anesthesia Associates

MEDNAX, Inc., today announced the acquisition of Holston Anesthesia Associates, P.C., a physician group practice based in Kingsport, Tenn. The practice will become part of MEDNAX's American Anesthesiology division and is the third Tennessee-based anesthesiology practice to join this division.

5 Aug 2013

FDA accepts NDA for MNK-795 oral formulation

Depomed, Inc. (NASDAQ: DEPO) announced today that the U. S. Food and Drug Administration (FDA) has accepted for filing a New Drug Application (NDA) from Mallinckrodt (NYSE: MNK) for MNK-795.

30 Jul 2013

Imprimis to begin IRB-approved Impracor Phase III trial for acute pain associated with OA of the knee

Imprimis Pharmaceuticals, Inc., which is focused on the commercialization of compounded drug formulations utilizing the FDA 505(b)(2) development pathway, today announced it has received IRB approval for its Phase III clinical trial protocol of its lead product candidate, Impracor.

23 Jul 2013

FDA accepts Iroko's submicron indomethacin NDA for treatment of acute pain in adults

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to scientific advancements in analgesia, announced that the U.S. Food and Drug Administration has accepted for review the New Drug Application for lower dose submicron indomethacin, a non-steroidal anti-inflammatory drug, for the proposed indication of treatment of mild to moderate acute pain in adults.

16 Jul 2013

Regional anesthesia improves outcomes in sleep apnea patients undergoing total joint arthroplasty

Using regional anesthesia instead of general anesthesia in patients with sleep apnea undergoing total joint replacement decreases major complications by 17%, according to a study published online, ahead of print, in the journal Regional Anesthesia and Pain Medicine.

3 May 2013

AcelRx Pharmaceuticals reports clinical results of Sufentanil NanoTab PCA System for acute pain treatment

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported additional clinical results for its lead product candidate, the Sufentanil NanoTab PCA System for the treatment of moderate-to-severe acute pain in the hospital setting.

2 May 2013